3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Warts
2
Melanoma
2
Hyperthermia
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell
1
Hemorrhage
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Cisplatin
22
pembrolizumab
21
Carboplatin
12
Radiotherapy
11
Paclitaxel
11
Brachytherapy
11
Drug Therapy
10
Bevacizumab
9
Blood Specimen Collection
7
Colposcopy
6
Specimen Handling
5
Injections
5
toripalimab
4
Taxes
4
Surveys and Questionnaires
4
Nivolumab
4
Mass Screening
4
Human Papillomavirus DNA Tests
4
Gemcitabine
4
Chemotherapy, Adjuvant
4
Chemoradiotherapy
4
spartalizumab
3
lenvatinib
3
camrelizumab
3
aldesleukin
3
Restraint, Physical
3
Radiation
3
Fulvestrant
3
Cyclophosphamide
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Uterine Cervical Neoplasms
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled